Arctic Therapeutics closed an oversubscribed US$21.5 million financing to advance AT-002 and AT-003 toward clinical development.
- Amount
- $21.5M
- Announced
- 21 October 2026
- Leads
- Pekron, Sanos Group, Kaldbakur, Landvættir
- Use of funds
- Advance AT-002 and AT-003 towards clinical development, expanding the clinical pipeline.
- Checked
- Announced by the company